Olivier Le Moal
- Q BioMed (OTCQB:QBIO) said its chemotherapeutic Uttroside B is expected to receive a patent in the U.S linked to liver cancer
- The company noted that it received a notice of allowance from the U.S. Patent Office for the patent titled 'Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma (HCC).'
- Q BioMed said it has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology in India, and the Oklahoma Medical Research Foundation.
- The company added that results from pre-clinical pharmacokinetic testing have been encouraging and the data supports advancing the program.